Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Acceleron Pharma (XLRN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,190,157
  • Shares Outstanding, K 52,686
  • Annual Sales, $ 13,990 K
  • Annual Income, $ -118,870 K
  • 60-Month Beta 1.31
  • Price/Sales 156.54
  • Price/Cash Flow N/A
  • Price/Book 4.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/19
See More
  • Average Estimate -0.23
  • Number of Estimates 6
  • High Estimate -0.11
  • Low Estimate -0.35
  • Prior Year -0.63
  • Growth Rate Est. (year over year) +63.49%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.50 +6.48%
on 05/03/19
43.36 -3.00%
on 05/22/19
+1.52 (+3.75%)
since 04/24/19
3-Month
38.65 +8.82%
on 04/18/19
48.11 -12.58%
on 04/02/19
-0.68 (-1.59%)
since 02/22/19
52-Week
32.53 +29.30%
on 06/28/18
59.59 -29.42%
on 09/21/18
+5.49 (+15.01%)
since 05/24/18

Most Recent Stories

More News
Acceleron to Present at the UBS Global Healthcare Conference

Acceleron Pharma Inc. (Nasdaq:XLRN), a leading biopharmaceutical company in the discovery and development of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced...

XLRN : 42.06 (+1.18%)
Acceleron Pharma (XLRN) Reports Q1 Loss, Misses Revenue Estimates

Acceleron (XLRN) delivered earnings and revenue surprises of -10.45% and -24.76%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

XLRN : 42.06 (+1.18%)
Acceleron: 1Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Acceleron Pharma Inc. (XLRN) on Thursday reported a loss of $38.1 million in its first quarter.

XLRN : 42.06 (+1.18%)
Acceleron Reports First Quarter 2019 Operating and Financial Results

--- Part 2 results from the ACE-083 Phase 2 trials in facioscapulohumeral muscular dystrophy (FSHD) expected in the second half of 2019 and Charcot-Marie-Tooth disease (CMT) anticipated in Q1 2020 -

XLRN : 42.06 (+1.18%)
The Zacks Analyst Blog Highlights: SunPower, Rosehill Resources, Legg Mason, Chaparral Energy and Acceleron Pharma

The Zacks Analyst Blog Highlights: SunPower, Rosehill Resources, Legg Mason, Chaparral Energy and Acceleron Pharma

LM : 37.21 (+0.84%)
XLRN : 42.06 (+1.18%)
ROSE : 3.17 (-8.91%)
CHAP : 4.06 (+0.50%)
SPWR : 7.78 (+0.65%)
Drug/Biotech Stock Q1 Earnings on May 9: IONS, XLRN & More

Five drug/biotech stocks are scheduled to release their first-quarter results on May 9. Let's take a look at how these companies are poised ahead of their earnings release.

GH : 77.00 (+1.57%)
PDLI : 2.96 (-0.67%)
MRK : 81.17 (+0.19%)
XLRN : 42.06 (+1.18%)
IONS : 64.72 (-3.60%)
BPMC : 84.68 (+2.09%)
PFE : 41.95 (+0.07%)
5 Must-Buy Stocks Ahead of Q1 Earnings Amid Market Volatility

First-quarter 2019 earnings results so far are better than expected.

LM : 37.21 (+0.84%)
XLRN : 42.06 (+1.18%)
ROSE : 3.17 (-8.91%)
CHAP : 4.06 (+0.50%)
SPWR : 7.78 (+0.65%)
Will Life Sciences Sales Boost Bio-Rad's (BIO) Q1 Earnings?

Within the Life Sciences segment, high investment in several geographies along with product launches and new technologies is resulting in a strong upside for Bio-Rad (BIO).

BIO : 293.37 (-0.20%)
XLRN : 42.06 (+1.18%)
NTGN : 5.21 (+0.19%)
UMRX : 3.29 (-0.60%)
Telenav (TNAV) to Report Q3 Earnings: What's in the Offing?

For the fiscal third quarter, Telenav (TNAV) expects total revenues between $49 million and $53 million, while net loss is anticipated to be $7 million-$9 million.

BMA : 49.99 (+3.39%)
TNAV : 7.54 (+0.53%)
XLRN : 42.06 (+1.18%)
YPF : 15.41 (+3.49%)
Can Epidolex Drive GW Pharmaceuticals' (GWPH) Q2 Earnings?

Following the U.S.-commercial launch of Epidolex last November, GW Pharmaceuticals (GWPH) continues to see an uptick from the same.

GWPH : 183.62 (-0.58%)
XLRN : 42.06 (+1.18%)
NTGN : 5.21 (+0.19%)
UMRX : 3.29 (-0.60%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More Share

Trade XLRN with:

Business Summary

Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

2nd Resistance Point 43.13
1st Resistance Point 42.60
Last Price 42.06
1st Support Level 41.56
2nd Support Level 41.06

See More

52-Week High 59.59
Fibonacci 61.8% 49.25
Fibonacci 50% 46.06
Fibonacci 38.2% 42.87
Last Price 42.06
52-Week Low 32.53

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar